

AMENDMENTS TO THE CLAIMS:

1. (Original) Crystalline compound of 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H)10-dioxo-2H-1,2,3-triazolo[4,5-c][1] benzazepine which has diffraction peaks at diffraction angles (2θ): $11.2 \pm 0.1^\circ$, $14.4 \pm 0.1^\circ$, $15.5 \pm 0.1^\circ$, and $25.3 \pm 0.1^\circ$ in a powder X-ray diffraction pattern.

2. (Original) The crystalline compound according to claim 1, which has a purity of not less than 99% as determined based on percentage area obtained by HPLC (high-performance liquid chromatography).

3. (Original) The crystalline compound according to claim 1 or 2, which has a melting point in the temperature range of 240 to 246°C (with decomposition) as determined from an endothermic peak in a DSC (differential scanning calorimetry) chart obtained by DSC.

4. **(Currently amended)** A pharmaceutical composition comprising the crystalline compound according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.

Claims 5-9. **(Cancelled)**.